Tarsus Pharmaceuticals (TARS) Competitors $43.36 -0.55 (-1.25%) As of 12:37 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TARS vs. BPMC, BBIO, ELAN, VRNA, TLX, GRFS, TGTX, LEGN, NUVL, and AXSMShould you be buying Tarsus Pharmaceuticals stock or one of its competitors? The main competitors of Tarsus Pharmaceuticals include Blueprint Medicines (BPMC), BridgeBio Pharma (BBIO), Elanco Animal Health (ELAN), Verona Pharma (VRNA), Telix Pharmaceuticals Limited American Depositary Shares (TLX), Grifols (GRFS), TG Therapeutics (TGTX), Legend Biotech (LEGN), Nuvalent (NUVL), and Axsome Therapeutics (AXSM). These companies are all part of the "pharmaceutical products" industry. Tarsus Pharmaceuticals vs. Blueprint Medicines BridgeBio Pharma Elanco Animal Health Verona Pharma Telix Pharmaceuticals Limited American Depositary Shares Grifols TG Therapeutics Legend Biotech Nuvalent Axsome Therapeutics Tarsus Pharmaceuticals (NASDAQ:TARS) and Blueprint Medicines (NASDAQ:BPMC) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, community ranking, profitability, institutional ownership, valuation and earnings. Does the MarketBeat Community believe in TARS or BPMC? Blueprint Medicines received 499 more outperform votes than Tarsus Pharmaceuticals when rated by MarketBeat users. However, 67.90% of users gave Tarsus Pharmaceuticals an outperform vote while only 67.40% of users gave Blueprint Medicines an outperform vote. CompanyUnderperformOutperformTarsus PharmaceuticalsOutperform Votes5567.90% Underperform Votes2632.10% Blueprint MedicinesOutperform Votes55467.40% Underperform Votes26832.60% Is TARS or BPMC more profitable? Blueprint Medicines has a net margin of -13.19% compared to Tarsus Pharmaceuticals' net margin of -103.64%. Tarsus Pharmaceuticals' return on equity of -55.86% beat Blueprint Medicines' return on equity.Company Net Margins Return on Equity Return on Assets Tarsus Pharmaceuticals-103.64% -55.86% -39.28% Blueprint Medicines -13.19%-77.49%-20.84% Do analysts recommend TARS or BPMC? Tarsus Pharmaceuticals currently has a consensus price target of $66.67, indicating a potential upside of 53.75%. Blueprint Medicines has a consensus price target of $125.59, indicating a potential downside of 1.91%. Given Tarsus Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Tarsus Pharmaceuticals is more favorable than Blueprint Medicines.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tarsus Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00Blueprint Medicines 0 Sell rating(s) 14 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.38 Does the media prefer TARS or BPMC? In the previous week, Blueprint Medicines had 44 more articles in the media than Tarsus Pharmaceuticals. MarketBeat recorded 61 mentions for Blueprint Medicines and 17 mentions for Tarsus Pharmaceuticals. Tarsus Pharmaceuticals' average media sentiment score of 0.94 beat Blueprint Medicines' score of 0.46 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tarsus Pharmaceuticals 5 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Blueprint Medicines 14 Very Positive mention(s) 11 Positive mention(s) 22 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals hold more shares of TARS or BPMC? 90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. 8.3% of Tarsus Pharmaceuticals shares are owned by insiders. Comparatively, 4.2% of Blueprint Medicines shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has preferable valuation and earnings, TARS or BPMC? Blueprint Medicines has higher revenue and earnings than Tarsus Pharmaceuticals. Blueprint Medicines is trading at a lower price-to-earnings ratio than Tarsus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTarsus Pharmaceuticals$233.67M7.80-$135.89M-$2.73-15.88Blueprint Medicines$562.12M14.71-$67.09M-$2.47-51.84 Which has more volatility and risk, TARS or BPMC? Tarsus Pharmaceuticals has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500. Comparatively, Blueprint Medicines has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500. SummaryTarsus Pharmaceuticals and Blueprint Medicines tied by winning 9 of the 18 factors compared between the two stocks. Get Tarsus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TARS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TARS vs. The Competition Export to ExcelMetricTarsus PharmaceuticalsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.82B$3.06B$5.48B$8.56BDividend YieldN/A1.60%5.26%4.20%P/E Ratio-11.3832.0327.1619.93Price / Sales7.80460.17436.37147.95Price / CashN/A168.6838.2534.64Price / Book7.293.376.834.62Net Income-$135.89M-$72.17M$3.23B$248.05M7 Day Performance3.12%6.46%3.51%2.16%1 Month Performance-8.45%4.72%7.15%7.75%1 Year Performance31.35%-16.59%27.92%11.36% Tarsus Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TARSTarsus Pharmaceuticals3.4448 of 5 stars$43.36-1.3%$66.67+53.8%+34.6%$1.82B$233.67M-11.3850Analyst ForecastBPMCBlueprint Medicines0.965 of 5 stars$101.50+1.2%$126.56+24.7%+21.7%$6.56B$562.12M-93.98640Trending NewsAnalyst DowngradeBBIOBridgeBio Pharma4.5119 of 5 stars$33.34+1.1%$57.09+71.2%+29.5%$6.33B$127.42M-11.70400Positive NewsELANElanco Animal Health2.0682 of 5 stars$12.66-0.1%$15.17+19.8%-24.1%$6.29B$4.43B31.669,800Positive NewsVRNAVerona Pharma1.5801 of 5 stars$75.06+3.3%$81.50+8.6%+609.1%$6.09B$118.54M-39.0930Analyst ForecastTLXTelix Pharmaceuticals Limited American Depositary SharesN/A$16.60+2.5%$22.00+32.5%N/A$5.61B$783.21M0.00N/APositive NewsHigh Trading VolumeGRFSGrifols2.7961 of 5 stars$8.11-0.2%N/A+13.5%$5.58B$7.21B6.9326,300TGTXTG Therapeutics3.7952 of 5 stars$34.57+1.0%$40.80+18.0%+123.0%$5.49B$386.39M-345.67290Positive NewsLEGNLegend Biotech3.2225 of 5 stars$28.91-0.5%$76.20+163.6%-29.0%$5.31B$728.30M-30.431,070Positive NewsNUVLNuvalent2.3835 of 5 stars$73.49+0.4%$115.50+57.2%+13.4%$5.26BN/A-21.1840Positive NewsAXSMAxsome Therapeutics4.8342 of 5 stars$105.07+0.7%$172.14+63.8%+47.3%$5.17B$432.16M-17.54380Analyst Forecast Related Companies and Tools Related Companies Blueprint Medicines Alternatives BridgeBio Pharma Alternatives Elanco Animal Health Alternatives Verona Pharma Alternatives Telix Pharmaceuticals Limited American Depositary Shares Alternatives Grifols Alternatives TG Therapeutics Alternatives Legend Biotech Alternatives Nuvalent Alternatives Axsome Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TARS) was last updated on 6/4/2025 by MarketBeat.com Staff From Our PartnersThe Real Reason Silver Prices Are SoaringElon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredFPV Drone Innovator Secures Major Defense ContractIn May, Ukraine launched Operation Spider Web - a 117-drone FPV swarm that devastated Russian fuel depots and ...The Tomorrow Investor | SponsoredJunior Explorer Taps Into TSMC’s $165 Billion Chip CorridorThe chip war is moving underground. As the U.S. ramps up semiconductor production to outpace China, an unex...Capital Trends | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThe Recession Already Started, Are You Prepared?Global central banks are stockpiling gold. Billionaires are hedging with precious metals. And thousands of Ame...Lear Capital | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tarsus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tarsus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TARS Stock Free TARS Stock Alerts